Compare DBI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | TTRX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.2M | 281.2M |
| IPO Year | 2005 | N/A |
| Metric | DBI | TTRX |
|---|---|---|
| Price | $6.23 | $7.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 519.1K | 126.1K |
| Earning Date | 06-09-2026 | 05-31-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 15.00 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,892,671,000.00 | N/A |
| Revenue This Year | $1.29 | N/A |
| Revenue Next Year | $1.88 | N/A |
| P/E Ratio | $320.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $2.57 |
| 52 Week High | $9.17 | $11.69 |
| Indicator | DBI | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 41.40 |
| Support Level | $5.96 | $4.40 |
| Resistance Level | $8.28 | $10.48 |
| Average True Range (ATR) | 0.32 | 0.84 |
| MACD | 0.12 | -0.37 |
| Stochastic Oscillator | 72.06 | 0.24 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.